Genmab — Juli 2024
-
-
Roche YTD June 2024 Lunsumio CHF37mn Columvi CHF 67mn (Q1 '24 Lunsumio CHF16mn Columvi CHF 25mn) https://assets.roche.com/f/176343/x/ca635dfd8b/240725_ir_hy.pdf https://assets.roche.com/f/176343/x/26b92ed3d9/irp240725-a.pdf
-
also, Ocrevus 3,359mn YTD, not growing much atm, but that may change again with SC dosing https://x.com/Biotech2050/status/1816360745887752508/photo/2
-
Kort video: Sommerpanik på aktiemarkederne https://proinvestor.com/boards/121481
-
Genmabs kræfthåb viser fortsat solide vækstrater https://proinvestor.com/investornyt/1190236/genmabs-kraefthab-viser-fortsat-solide-vaekstrater
-
ADS i usa stiger med 1% - svarende til den danske notering..
-
Torsdagens aktier: Genmab skilte sig positivt ud i presset C25 https://proinvestor.com/investornyt/1190286/torsdagens-aktier-genmab-skilte-sig-positivt-ud-i-presset-c25
-
@Pensionisten med 1% stigning i US. så får jeg kursen til 1930dkr
-
Epkinly $17/27/63 mln i hhv Q4/Q1/Q2 jf https://proinvestor.com/investornyt/1190236/genmabs-kraefthab-viser-fortsat-solide-vaekstrater - det tegner godt

Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind